Where Will Viking Therapeutics Be in 3 Years? Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' pocketbooks.
Rates Spark: U.S. Treasuries Primed To React Should Friday's payrolls come in as expected, little reaction is likely though. The biggest reaction would come from a materially weak number.
